ART Persistence in Different Body Compartments in HIV Negative MSM
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
The study seeks to understand how anti-HIV drug Biktarvy -
tenofovir+emtricitabine+bictegrativir (TAF/FTC/BIC) is absorbed and how long it persists in
different body compartments, including mucosal tissues, as it may be considered for PrEP or
PEP regimens in the future.